Analysis of Solvency Ratios
Solvency ratios also known as long-term debt ratios measure a company’s ability to meet long-term obligations.
Solvency Ratios (Summary)
Regeneron Pharmaceuticals Inc., solvency ratios
Based on: 10-K (filing date: 2020-02-07), 10-K (filing date: 2019-02-07), 10-K (filing date: 2018-02-08), 10-K (filing date: 2017-02-09), 10-K (filing date: 2016-02-11).
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to equity ratio | A solvency ratio calculated as total debt divided by total shareholders’ equity. | Regeneron Pharmaceuticals Inc.’s debt to equity ratio improved from 2017 to 2018 and from 2018 to 2019. |
| Debt to equity ratio (including operating lease liability) | A solvency ratio calculated as total debt (including operating lease liability) divided by total shareholders’ equity. | Regeneron Pharmaceuticals Inc.’s debt to equity ratio (including operating lease liability) improved from 2017 to 2018 and from 2018 to 2019. |
| Debt to capital ratio | A solvency ratio calculated as total debt divided by total debt plus shareholders’ equity. | Regeneron Pharmaceuticals Inc.’s debt to capital ratio improved from 2017 to 2018 and from 2018 to 2019. |
| Debt to capital ratio (including operating lease liability) | A solvency ratio calculated as total debt (including operating lease liability) divided by total debt (including operating lease liability) plus shareholders’ equity. | Regeneron Pharmaceuticals Inc.’s debt to capital ratio (including operating lease liability) improved from 2017 to 2018 and from 2018 to 2019. |
| Debt to assets ratio | A solvency ratio calculated as total debt divided by total assets. | Regeneron Pharmaceuticals Inc.’s debt to assets ratio improved from 2017 to 2018 and from 2018 to 2019. |
| Debt to assets ratio (including operating lease liability) | A solvency ratio calculated as total debt (including operating lease liability) divided by total assets. | Regeneron Pharmaceuticals Inc.’s debt to assets ratio (including operating lease liability) improved from 2017 to 2018 and from 2018 to 2019. |
| Financial leverage ratio | A solvency ratio calculated as total assets divided by total shareholders’ equity. | Regeneron Pharmaceuticals Inc.’s financial leverage ratio decreased from 2017 to 2018 and from 2018 to 2019. |
| Solvency ratio | Description | The company |
|---|---|---|
| Interest coverage ratio | A solvency ratio calculated as EBIT divided by interest payments. | Regeneron Pharmaceuticals Inc.’s interest coverage ratio improved from 2017 to 2018 but then deteriorated significantly from 2018 to 2019. |
Debt to Equity
Regeneron Pharmaceuticals Inc., debt to equity calculation, comparison to benchmarks
| Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Finance lease liabilities, current portion | — | — | — | 129,557 | 1,789 | |
| Convertible senior notes, current portion | — | — | — | — | 10,802 | |
| Finance lease liabilities, excluding current portion | 713,900 | 708,500 | 703,453 | 351,569 | 362,919 | |
| Total debt | 713,900 | 708,500 | 703,453 | 481,126 | 375,510 | |
| Stockholders’ equity | 11,089,700 | 8,757,300 | 6,144,078 | 4,449,245 | 3,654,837 | |
| Solvency Ratio | ||||||
| Debt to equity1 | 0.06 | 0.08 | 0.11 | 0.11 | 0.10 | |
| Benchmarks | ||||||
| Debt to Equity, Competitors2 | ||||||
| Abbott Laboratories | 0.58 | 0.64 | 0.90 | 1.07 | 0.42 | |
| AbbVie Inc. | — | — | 7.33 | 7.95 | 8.03 | |
| Amgen Inc. | 3.09 | 2.71 | 1.40 | 1.16 | 1.12 | |
| Bristol-Myers Squibb Co. | 0.91 | 0.52 | 0.68 | 0.41 | 0.47 | |
| Eli Lilly & Co. | 5.88 | 1.30 | 1.18 | 0.74 | 0.55 | |
| Gilead Sciences Inc. | 1.09 | 1.28 | 1.64 | 1.39 | 1.20 | |
| Illumina Inc. | 0.25 | 0.53 | 0.49 | 0.58 | 0.60 | |
| Johnson & Johnson | 0.47 | 0.51 | 0.57 | 0.39 | 0.28 | |
| Merck & Co. Inc. | 1.02 | 0.94 | 0.71 | 0.62 | 0.59 | |
| Pfizer Inc. | 0.83 | 0.66 | 0.61 | 0.71 | 0.60 | |
| Vertex Pharmaceuticals Inc. | 0.09 | 0.13 | 0.29 | 0.71 | 0.86 | |
| Zoetis Inc. | 2.38 | 2.95 | 2.80 | 3.00 | 4.56 | |
| Debt to Equity, Sector | ||||||
| Pharmaceuticals & Biotechnology | 1.12 | 1.00 | 0.94 | 0.84 | 0.70 | |
| Debt to Equity, Industry | ||||||
| Health Care | 0.91 | 0.83 | 0.84 | 0.79 | 0.71 | |
Based on: 10-K (filing date: 2020-02-07), 10-K (filing date: 2019-02-07), 10-K (filing date: 2018-02-08), 10-K (filing date: 2017-02-09), 10-K (filing date: 2016-02-11).
1 2019 Calculation
Debt to equity = Total debt ÷ Stockholders’ equity
= 713,900 ÷ 11,089,700 = 0.06
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to equity ratio | A solvency ratio calculated as total debt divided by total shareholders’ equity. | Regeneron Pharmaceuticals Inc.’s debt to equity ratio improved from 2017 to 2018 and from 2018 to 2019. |
Debt to Equity (including Operating Lease Liability)
Regeneron Pharmaceuticals Inc., debt to equity (including operating lease liability) calculation, comparison to benchmarks
| Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Finance lease liabilities, current portion | — | — | — | 129,557 | 1,789 | |
| Convertible senior notes, current portion | — | — | — | — | 10,802 | |
| Finance lease liabilities, excluding current portion | 713,900 | 708,500 | 703,453 | 351,569 | 362,919 | |
| Total debt | 713,900 | 708,500 | 703,453 | 481,126 | 375,510 | |
| Operating lease liabilities (included in Accrued expenses and other current liabilities) | 7,600 | — | — | — | — | |
| Operating lease liabilities (included in Other noncurrent liabilities) | 16,000 | — | — | — | — | |
| Total debt (including operating lease liability) | 737,500 | 708,500 | 703,453 | 481,126 | 375,510 | |
| Stockholders’ equity | 11,089,700 | 8,757,300 | 6,144,078 | 4,449,245 | 3,654,837 | |
| Solvency Ratio | ||||||
| Debt to equity (including operating lease liability)1 | 0.07 | 0.08 | 0.11 | 0.11 | 0.10 | |
| Benchmarks | ||||||
| Debt to Equity (including Operating Lease Liability), Competitors2 | ||||||
| Abbott Laboratories | 0.61 | 0.64 | 0.90 | 1.07 | 0.42 | |
| AbbVie Inc. | — | — | 7.33 | 7.95 | 8.03 | |
| Amgen Inc. | 3.15 | 2.71 | 1.40 | 1.16 | 1.12 | |
| Bristol-Myers Squibb Co. | 0.92 | 0.52 | 0.68 | 0.41 | 0.47 | |
| Eli Lilly & Co. | 6.11 | 1.30 | 1.18 | 0.74 | 0.55 | |
| Gilead Sciences Inc. | 1.12 | 1.28 | 1.64 | 1.39 | 1.20 | |
| Illumina Inc. | 0.41 | 0.53 | 0.49 | 0.58 | 0.60 | |
| Johnson & Johnson | 0.48 | 0.51 | 0.57 | 0.39 | 0.28 | |
| Merck & Co. Inc. | 1.06 | 0.94 | 0.71 | 0.62 | 0.59 | |
| Pfizer Inc. | 0.85 | 0.66 | 0.61 | 0.71 | 0.60 | |
| Vertex Pharmaceuticals Inc. | 0.11 | 0.13 | 0.29 | 0.71 | 0.86 | |
| Zoetis Inc. | 2.45 | 2.95 | 2.80 | 3.00 | 4.56 | |
| Debt to Equity (including Operating Lease Liability), Sector | ||||||
| Pharmaceuticals & Biotechnology | 1.15 | 1.00 | 0.94 | 0.84 | 0.70 | |
| Debt to Equity (including Operating Lease Liability), Industry | ||||||
| Health Care | 0.94 | 0.83 | 0.84 | 0.79 | 0.71 | |
Based on: 10-K (filing date: 2020-02-07), 10-K (filing date: 2019-02-07), 10-K (filing date: 2018-02-08), 10-K (filing date: 2017-02-09), 10-K (filing date: 2016-02-11).
1 2019 Calculation
Debt to equity (including operating lease liability) = Total debt (including operating lease liability) ÷ Stockholders’ equity
= 737,500 ÷ 11,089,700 = 0.07
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to equity ratio (including operating lease liability) | A solvency ratio calculated as total debt (including operating lease liability) divided by total shareholders’ equity. | Regeneron Pharmaceuticals Inc.’s debt to equity ratio (including operating lease liability) improved from 2017 to 2018 and from 2018 to 2019. |
Debt to Capital
Regeneron Pharmaceuticals Inc., debt to capital calculation, comparison to benchmarks
| Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Finance lease liabilities, current portion | — | — | — | 129,557 | 1,789 | |
| Convertible senior notes, current portion | — | — | — | — | 10,802 | |
| Finance lease liabilities, excluding current portion | 713,900 | 708,500 | 703,453 | 351,569 | 362,919 | |
| Total debt | 713,900 | 708,500 | 703,453 | 481,126 | 375,510 | |
| Stockholders’ equity | 11,089,700 | 8,757,300 | 6,144,078 | 4,449,245 | 3,654,837 | |
| Total capital | 11,803,600 | 9,465,800 | 6,847,531 | 4,930,371 | 4,030,347 | |
| Solvency Ratio | ||||||
| Debt to capital1 | 0.06 | 0.07 | 0.10 | 0.10 | 0.09 | |
| Benchmarks | ||||||
| Debt to Capital, Competitors2 | ||||||
| Abbott Laboratories | 0.37 | 0.39 | 0.47 | 0.52 | 0.30 | |
| AbbVie Inc. | 1.14 | 1.27 | 0.88 | 0.89 | 0.89 | |
| Amgen Inc. | 0.76 | 0.73 | 0.58 | 0.54 | 0.53 | |
| Bristol-Myers Squibb Co. | 0.48 | 0.34 | 0.40 | 0.29 | 0.32 | |
| Eli Lilly & Co. | 0.85 | 0.57 | 0.54 | 0.42 | 0.35 | |
| Gilead Sciences Inc. | 0.52 | 0.56 | 0.62 | 0.58 | 0.54 | |
| Illumina Inc. | 0.20 | 0.35 | 0.33 | 0.37 | 0.37 | |
| Johnson & Johnson | 0.32 | 0.34 | 0.37 | 0.28 | 0.22 | |
| Merck & Co. Inc. | 0.50 | 0.48 | 0.42 | 0.38 | 0.37 | |
| Pfizer Inc. | 0.45 | 0.40 | 0.38 | 0.41 | 0.38 | |
| Vertex Pharmaceuticals Inc. | 0.09 | 0.12 | 0.22 | 0.42 | 0.46 | |
| Zoetis Inc. | 0.70 | 0.75 | 0.74 | 0.75 | 0.82 | |
| Debt to Capital, Sector | ||||||
| Pharmaceuticals & Biotechnology | 0.53 | 0.50 | 0.48 | 0.46 | 0.41 | |
| Debt to Capital, Industry | ||||||
| Health Care | 0.48 | 0.45 | 0.46 | 0.44 | 0.41 | |
Based on: 10-K (filing date: 2020-02-07), 10-K (filing date: 2019-02-07), 10-K (filing date: 2018-02-08), 10-K (filing date: 2017-02-09), 10-K (filing date: 2016-02-11).
1 2019 Calculation
Debt to capital = Total debt ÷ Total capital
= 713,900 ÷ 11,803,600 = 0.06
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to capital ratio | A solvency ratio calculated as total debt divided by total debt plus shareholders’ equity. | Regeneron Pharmaceuticals Inc.’s debt to capital ratio improved from 2017 to 2018 and from 2018 to 2019. |
Debt to Capital (including Operating Lease Liability)
Regeneron Pharmaceuticals Inc., debt to capital (including operating lease liability) calculation, comparison to benchmarks
| Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Finance lease liabilities, current portion | — | — | — | 129,557 | 1,789 | |
| Convertible senior notes, current portion | — | — | — | — | 10,802 | |
| Finance lease liabilities, excluding current portion | 713,900 | 708,500 | 703,453 | 351,569 | 362,919 | |
| Total debt | 713,900 | 708,500 | 703,453 | 481,126 | 375,510 | |
| Operating lease liabilities (included in Accrued expenses and other current liabilities) | 7,600 | — | — | — | — | |
| Operating lease liabilities (included in Other noncurrent liabilities) | 16,000 | — | — | — | — | |
| Total debt (including operating lease liability) | 737,500 | 708,500 | 703,453 | 481,126 | 375,510 | |
| Stockholders’ equity | 11,089,700 | 8,757,300 | 6,144,078 | 4,449,245 | 3,654,837 | |
| Total capital (including operating lease liability) | 11,827,200 | 9,465,800 | 6,847,531 | 4,930,371 | 4,030,347 | |
| Solvency Ratio | ||||||
| Debt to capital (including operating lease liability)1 | 0.06 | 0.07 | 0.10 | 0.10 | 0.09 | |
| Benchmarks | ||||||
| Debt to Capital (including Operating Lease Liability), Competitors2 | ||||||
| Abbott Laboratories | 0.38 | 0.39 | 0.47 | 0.52 | 0.30 | |
| AbbVie Inc. | 1.14 | 1.27 | 0.88 | 0.89 | 0.89 | |
| Amgen Inc. | 0.76 | 0.73 | 0.58 | 0.54 | 0.53 | |
| Bristol-Myers Squibb Co. | 0.48 | 0.34 | 0.40 | 0.29 | 0.32 | |
| Eli Lilly & Co. | 0.86 | 0.57 | 0.54 | 0.42 | 0.35 | |
| Gilead Sciences Inc. | 0.53 | 0.56 | 0.62 | 0.58 | 0.54 | |
| Illumina Inc. | 0.29 | 0.35 | 0.33 | 0.37 | 0.37 | |
| Johnson & Johnson | 0.33 | 0.34 | 0.37 | 0.28 | 0.22 | |
| Merck & Co. Inc. | 0.51 | 0.48 | 0.42 | 0.38 | 0.37 | |
| Pfizer Inc. | 0.46 | 0.40 | 0.38 | 0.41 | 0.38 | |
| Vertex Pharmaceuticals Inc. | 0.10 | 0.12 | 0.22 | 0.42 | 0.46 | |
| Zoetis Inc. | 0.71 | 0.75 | 0.74 | 0.75 | 0.82 | |
| Debt to Capital (including Operating Lease Liability), Sector | ||||||
| Pharmaceuticals & Biotechnology | 0.53 | 0.50 | 0.48 | 0.46 | 0.41 | |
| Debt to Capital (including Operating Lease Liability), Industry | ||||||
| Health Care | 0.48 | 0.45 | 0.46 | 0.44 | 0.41 | |
Based on: 10-K (filing date: 2020-02-07), 10-K (filing date: 2019-02-07), 10-K (filing date: 2018-02-08), 10-K (filing date: 2017-02-09), 10-K (filing date: 2016-02-11).
1 2019 Calculation
Debt to capital (including operating lease liability) = Total debt (including operating lease liability) ÷ Total capital (including operating lease liability)
= 737,500 ÷ 11,827,200 = 0.06
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to capital ratio (including operating lease liability) | A solvency ratio calculated as total debt (including operating lease liability) divided by total debt (including operating lease liability) plus shareholders’ equity. | Regeneron Pharmaceuticals Inc.’s debt to capital ratio (including operating lease liability) improved from 2017 to 2018 and from 2018 to 2019. |
Debt to Assets
Regeneron Pharmaceuticals Inc., debt to assets calculation, comparison to benchmarks
| Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Finance lease liabilities, current portion | — | — | — | 129,557 | 1,789 | |
| Convertible senior notes, current portion | — | — | — | — | 10,802 | |
| Finance lease liabilities, excluding current portion | 713,900 | 708,500 | 703,453 | 351,569 | 362,919 | |
| Total debt | 713,900 | 708,500 | 703,453 | 481,126 | 375,510 | |
| Total assets | 14,805,200 | 11,734,500 | 8,764,286 | 6,973,466 | 5,609,132 | |
| Solvency Ratio | ||||||
| Debt to assets1 | 0.05 | 0.06 | 0.08 | 0.07 | 0.07 | |
| Benchmarks | ||||||
| Debt to Assets, Competitors2 | ||||||
| Abbott Laboratories | 0.27 | 0.29 | 0.37 | 0.42 | 0.22 | |
| AbbVie Inc. | 0.75 | 0.68 | 0.53 | 0.56 | 0.60 | |
| Amgen Inc. | 0.50 | 0.51 | 0.44 | 0.45 | 0.44 | |
| Bristol-Myers Squibb Co. | 0.36 | 0.21 | 0.24 | 0.20 | 0.21 | |
| Eli Lilly & Co. | 0.39 | 0.29 | 0.30 | 0.27 | 0.22 | |
| Gilead Sciences Inc. | 0.40 | 0.43 | 0.48 | 0.46 | 0.43 | |
| Illumina Inc. | 0.16 | 0.29 | 0.25 | 0.30 | 0.30 | |
| Johnson & Johnson | 0.18 | 0.20 | 0.22 | 0.19 | 0.15 | |
| Merck & Co. Inc. | 0.31 | 0.30 | 0.28 | 0.26 | 0.26 | |
| Pfizer Inc. | 0.31 | 0.26 | 0.25 | 0.25 | 0.23 | |
| Vertex Pharmaceuticals Inc. | 0.07 | 0.09 | 0.16 | 0.28 | 0.32 | |
| Zoetis Inc. | 0.56 | 0.60 | 0.58 | 0.58 | 0.62 | |
| Debt to Assets, Sector | ||||||
| Pharmaceuticals & Biotechnology | 0.35 | 0.32 | 0.32 | 0.31 | 0.28 | |
| Debt to Assets, Industry | ||||||
| Health Care | 0.33 | 0.31 | 0.32 | 0.31 | 0.29 | |
Based on: 10-K (filing date: 2020-02-07), 10-K (filing date: 2019-02-07), 10-K (filing date: 2018-02-08), 10-K (filing date: 2017-02-09), 10-K (filing date: 2016-02-11).
1 2019 Calculation
Debt to assets = Total debt ÷ Total assets
= 713,900 ÷ 14,805,200 = 0.05
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to assets ratio | A solvency ratio calculated as total debt divided by total assets. | Regeneron Pharmaceuticals Inc.’s debt to assets ratio improved from 2017 to 2018 and from 2018 to 2019. |
Debt to Assets (including Operating Lease Liability)
Regeneron Pharmaceuticals Inc., debt to assets (including operating lease liability) calculation, comparison to benchmarks
| Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Finance lease liabilities, current portion | — | — | — | 129,557 | 1,789 | |
| Convertible senior notes, current portion | — | — | — | — | 10,802 | |
| Finance lease liabilities, excluding current portion | 713,900 | 708,500 | 703,453 | 351,569 | 362,919 | |
| Total debt | 713,900 | 708,500 | 703,453 | 481,126 | 375,510 | |
| Operating lease liabilities (included in Accrued expenses and other current liabilities) | 7,600 | — | — | — | — | |
| Operating lease liabilities (included in Other noncurrent liabilities) | 16,000 | — | — | — | — | |
| Total debt (including operating lease liability) | 737,500 | 708,500 | 703,453 | 481,126 | 375,510 | |
| Total assets | 14,805,200 | 11,734,500 | 8,764,286 | 6,973,466 | 5,609,132 | |
| Solvency Ratio | ||||||
| Debt to assets (including operating lease liability)1 | 0.05 | 0.06 | 0.08 | 0.07 | 0.07 | |
| Benchmarks | ||||||
| Debt to Assets (including Operating Lease Liability), Competitors2 | ||||||
| Abbott Laboratories | 0.28 | 0.29 | 0.37 | 0.42 | 0.22 | |
| AbbVie Inc. | 0.75 | 0.68 | 0.53 | 0.56 | 0.60 | |
| Amgen Inc. | 0.51 | 0.51 | 0.44 | 0.45 | 0.44 | |
| Bristol-Myers Squibb Co. | 0.37 | 0.21 | 0.24 | 0.20 | 0.21 | |
| Eli Lilly & Co. | 0.41 | 0.29 | 0.30 | 0.27 | 0.22 | |
| Gilead Sciences Inc. | 0.41 | 0.43 | 0.48 | 0.46 | 0.43 | |
| Illumina Inc. | 0.26 | 0.29 | 0.25 | 0.30 | 0.30 | |
| Johnson & Johnson | 0.18 | 0.20 | 0.22 | 0.19 | 0.15 | |
| Merck & Co. Inc. | 0.32 | 0.30 | 0.28 | 0.26 | 0.26 | |
| Pfizer Inc. | 0.32 | 0.26 | 0.25 | 0.25 | 0.23 | |
| Vertex Pharmaceuticals Inc. | 0.08 | 0.09 | 0.16 | 0.28 | 0.32 | |
| Zoetis Inc. | 0.58 | 0.60 | 0.58 | 0.58 | 0.62 | |
| Debt to Assets (including Operating Lease Liability), Sector | ||||||
| Pharmaceuticals & Biotechnology | 0.36 | 0.32 | 0.32 | 0.31 | 0.28 | |
| Debt to Assets (including Operating Lease Liability), Industry | ||||||
| Health Care | 0.34 | 0.31 | 0.32 | 0.31 | 0.29 | |
Based on: 10-K (filing date: 2020-02-07), 10-K (filing date: 2019-02-07), 10-K (filing date: 2018-02-08), 10-K (filing date: 2017-02-09), 10-K (filing date: 2016-02-11).
1 2019 Calculation
Debt to assets (including operating lease liability) = Total debt (including operating lease liability) ÷ Total assets
= 737,500 ÷ 14,805,200 = 0.05
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to assets ratio (including operating lease liability) | A solvency ratio calculated as total debt (including operating lease liability) divided by total assets. | Regeneron Pharmaceuticals Inc.’s debt to assets ratio (including operating lease liability) improved from 2017 to 2018 and from 2018 to 2019. |
Financial Leverage
Regeneron Pharmaceuticals Inc., financial leverage calculation, comparison to benchmarks
| Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Total assets | 14,805,200 | 11,734,500 | 8,764,286 | 6,973,466 | 5,609,132 | |
| Stockholders’ equity | 11,089,700 | 8,757,300 | 6,144,078 | 4,449,245 | 3,654,837 | |
| Solvency Ratio | ||||||
| Financial leverage1 | 1.34 | 1.34 | 1.43 | 1.57 | 1.53 | |
| Benchmarks | ||||||
| Financial Leverage, Competitors2 | ||||||
| Abbott Laboratories | 2.18 | 2.20 | 2.47 | 2.56 | 1.94 | |
| AbbVie Inc. | — | — | 13.89 | 14.26 | 13.45 | |
| Amgen Inc. | 6.17 | 5.31 | 3.17 | 2.60 | 2.55 | |
| Bristol-Myers Squibb Co. | 2.52 | 2.49 | 2.86 | 2.08 | 2.23 | |
| Eli Lilly & Co. | 15.07 | 4.47 | 3.88 | 2.77 | 2.44 | |
| Gilead Sciences Inc. | 2.74 | 2.98 | 3.44 | 3.02 | 2.80 | |
| Illumina Inc. | 1.59 | 1.85 | 1.91 | 1.95 | 1.99 | |
| Johnson & Johnson | 2.65 | 2.56 | 2.61 | 2.01 | 1.88 | |
| Merck & Co. Inc. | 3.26 | 3.09 | 2.56 | 2.38 | 2.28 | |
| Pfizer Inc. | 2.65 | 2.51 | 2.41 | 2.88 | 2.59 | |
| Vertex Pharmaceuticals Inc. | 1.37 | 1.41 | 1.75 | 2.50 | 2.66 | |
| Zoetis Inc. | 4.26 | 4.93 | 4.85 | 5.14 | 7.41 | |
| Financial Leverage, Sector | ||||||
| Pharmaceuticals & Biotechnology | 3.18 | 3.08 | 2.89 | 2.67 | 2.45 | |
| Financial Leverage, Industry | ||||||
| Health Care | 2.77 | 2.68 | 2.66 | 2.54 | 2.41 | |
Based on: 10-K (filing date: 2020-02-07), 10-K (filing date: 2019-02-07), 10-K (filing date: 2018-02-08), 10-K (filing date: 2017-02-09), 10-K (filing date: 2016-02-11).
1 2019 Calculation
Financial leverage = Total assets ÷ Stockholders’ equity
= 14,805,200 ÷ 11,089,700 = 1.34
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Financial leverage ratio | A solvency ratio calculated as total assets divided by total shareholders’ equity. | Regeneron Pharmaceuticals Inc.’s financial leverage ratio decreased from 2017 to 2018 and from 2018 to 2019. |
Interest Coverage
Regeneron Pharmaceuticals Inc., interest coverage calculation, comparison to benchmarks
| Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Net income | 2,115,800 | 2,444,400 | 1,198,511 | 895,522 | 636,056 | |
| Add: Income tax expense | 313,300 | 109,100 | 880,000 | 434,293 | 589,041 | |
| Add: Interest expense | 30,200 | 28,200 | 25,119 | 7,195 | 14,241 | |
| Earnings before interest and tax (EBIT) | 2,459,300 | 2,581,700 | 2,103,630 | 1,337,010 | 1,239,338 | |
| Solvency Ratio | ||||||
| Interest coverage1 | 81.43 | 91.55 | 83.75 | 185.82 | 87.03 | |
| Benchmarks | ||||||
| Interest Coverage, Competitors2 | ||||||
| Abbott Laboratories | 7.09 | 4.48 | 3.47 | 4.28 | 20.53 | |
| AbbVie Inc. | 5.72 | 4.86 | 7.72 | 8.53 | 10.24 | |
| Amgen Inc. | 8.09 | 7.86 | 8.36 | 8.27 | 8.29 | |
| Bristol-Myers Squibb Co. | 8.58 | 33.61 | 27.18 | 36.42 | 12.29 | |
| Eli Lilly & Co. | 14.15 | 14.95 | 10.77 | 19.22 | 18.31 | |
| Gilead Sciences Inc. | 6.19 | 8.24 | 13.10 | 18.74 | 32.48 | |
| Illumina Inc. | 22.50 | 16.68 | 29.19 | 17.91 | 14.84 | |
| Johnson & Johnson | 55.49 | 18.91 | 19.92 | 28.28 | 35.78 | |
| Merck & Co. Inc. | 13.84 | 12.27 | 9.65 | 7.72 | 9.04 | |
| Pfizer Inc. | 12.23 | 10.03 | 10.69 | 8.04 | 8.48 | |
| Vertex Pharmaceuticals Inc. | 24.84 | 9.28 | 0.77 | 0.17 | -5.62 | |
| Zoetis Inc. | 9.08 | 9.20 | 9.71 | 8.40 | 5.40 | |
| Interest Coverage, Sector | ||||||
| Pharmaceuticals & Biotechnology | 11.09 | 10.29 | 10.99 | 12.62 | 14.99 | |
| Interest Coverage, Industry | ||||||
| Health Care | 9.95 | 9.71 | 10.14 | 10.74 | 12.97 | |
Based on: 10-K (filing date: 2020-02-07), 10-K (filing date: 2019-02-07), 10-K (filing date: 2018-02-08), 10-K (filing date: 2017-02-09), 10-K (filing date: 2016-02-11).
1 2019 Calculation
Interest coverage = EBIT ÷ Interest expense
= 2,459,300 ÷ 30,200 = 81.43
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Interest coverage ratio | A solvency ratio calculated as EBIT divided by interest payments. | Regeneron Pharmaceuticals Inc.’s interest coverage ratio improved from 2017 to 2018 but then deteriorated significantly from 2018 to 2019. |